Announcements Trials
Browse Landscape

Phase

Phase 1/2 1Phase 1 1

Status

Withdrawn 1Terminated 1

Sponsor Class

OTHER 1NIH 1

Study Type

Interventional 2

Sponsor

Cancer Type

Dermatologic 36CNS 5Thoracic 3Gynecologic 3Gastrointestinal 3Sarcoma 2Other hematologic neoplasm 2Lymphoid 2Genitourinary 2Breast 2Myeloid 1

Conditions

Triple Negative Breast Neoplasms 5Breast Neoplasms 5Neoplasm Metastasis 3Precursor Cell Lymphoblastic Leukemia-Lymphoma 2Ovarian Neoplasms 2Multiple Myeloma 2Melanoma 2Lymphoma, Non-Hodgkin 2Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative 2Leukemia, Myeloid, Acute 2Leukemia, Myelogenous, Chronic, BCR-ABL Positive 2Leukemia, Lymphocytic, Chronic, B-Cell 2Hodgkin Disease 2Uveal Melanoma 1Thyroid Carcinoma, Anaplastic 1Thrombocytosis 1Testicular Neoplasms 1Teratoma, Testicular 1Teratoma 1Seminoma 1Sarcoma 1Prostatic Neoplasms 1Primary Myelofibrosis 1Pancreatic Neoplasms 1Osteosarcoma 1Neuroblastoma 1Neoplasms 1Myeloproliferative Disorders 1Myelodysplastic-Myeloproliferative Diseases 1Myelodysplastic Syndromes 1

Interventions

pembrolizumab 44Cyclophosphamide 21Nivolumab 18fludarabine 10durvalumab 8Paclitaxel 8Magnetic Resonance Spectroscopy 8Interleukin-2 8Docetaxel 8aldesleukin 7Radiosurgery 7Ipilimumab 7spartalizumab 6poly ICLC 6fludarabine phosphate 6atezolizumab 6Specimen Handling 6Radiotherapy 6Carboplatin 6cemiplimab 5Drug Therapy 5Cisplatin 5Biopsy 5Temozolomide 4Immune Checkpoint Inhibitors 4tremelimumab 3technetium-diethylenetriaminepentaacetic acid-mannosyl-dextran 3pazopanib 3avelumab 3Trastuzumab 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Melanoma × CTLA-4 Antigen × Breast × Clear all
NCT02419495 2025-06-04

Phase IB Study to Evaluate the Safety of Selinexor (KPT-330) in Combination With Multiple Standard Chemotherapy or Immunotherapy Agents in Patients With Advanced Malignancies

M.D. Anderson Cancer Center

Phase 1 Terminated
221 enrolled
BreastDermatologicGenitourinaryGynecologicThoracic

Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Fallopian Tube Neoplasms, Lung Neoplasms, Melanoma, Neoplasm Metastasis, Ovarian Neoplasms, Triple Negative Breast Neoplasms

NCT03326258 2018-07-18

Glembatumumab Vedotin, Nivolumab, and Ipilimumab in Treating Patients With Advanced Metastatic Solid Tumors That Cannot Be Removed by Surgery

National Cancer Institute (NCI)

Phase 1/2 Withdrawn
BreastDermatologic

Uveal Melanoma, Breast Neoplasms, Melanoma, Neoplasm Metastasis, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡